文献速递乳腺癌支持与姑息治疗

手部冷却与加压预防紫杉烷诱导神经病变的疗效:POLAR随机临床试验

Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy: The POLAR Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2025-01-01

POLAR随机临床试验在德国海德堡国家肿瘤疾病中心纳入122例接受紫杉烷类化疗的原发性乳腺癌女性患者,按1:1随机对优势手进行冷却或加压,另一手不干预。冷却组和加压组均显著降低2级及以上感觉性化疗诱导的周围神经病变(CIPN)发生率。

要点

  • 冷却组2级及以上CIPN发生15例(29%),对照组26例(50%),P=.002。
  • 加压组2级及以上CIPN发生12例(24%),对照组19例(38%),P=.008。
  • CIPN是24例治疗终止者中16例(67%)的主要原因。

核心结论

  • 在这项随机临床试验中,冷却和加压均高度有效,显著降低了高级别CIPN的风险。

研究设计与样本

  • POLAR随机临床试验于2019年11月至2022年在海德堡国家肿瘤疾病中心开展。
  • 纳入接受每周白蛋白结合型紫杉醇或紫杉醇新辅助或辅助化疗的女性原发性乳腺癌患者。
  • 排除既往化疗、已有神经病变或神经病变相关合并症的患者。
  • 患者按1:1随机分配至优势手冷却或加压,另一手不干预。
  • 共122例女性原发性乳腺癌患者(平均[SD]年龄50[12]岁)随机分组,21例退出,最终分析纳入101例(冷却组n=52,加压组n=49)。

主要发现

  • 冷却组15例(29%)发生高级别CIPN,对照组26例(50%),P=.002,效应量21.15%(95%CI 5.98%-35.55%)。
  • 加压组12例(24%)发生CIPN,对照组19例(38%),P=.008,效应量14.29%(95%CI 2.02%-27.24%)。
  • CIPN是24例治疗终止者中16例(67%)的主要原因。
  • 主要风险因素为累积紫杉烷剂量和神经毒性药物。
  • 发生2级及以上CIPN的患者在紫杉烷治疗期间及治疗后6至8个月整体健康状况下降。

关键数值与推荐

  • 主要终点为采用不良事件通用术语标准第5.0版评估的2级及以上感觉性CIPN预防疗效。
  • 其他CIPN评估包括临床版总神经病变评分和QLQ CIPN20。
  • 随访检查在末次紫杉烷给药后1周、1个月和6至8个月进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting adverse effect of taxane-based chemotherapies. Currently, there is no established strategy for prevention or treatment. OBJECTIVE: To compare the effectiveness of 1-sided hand cooling and compression for preventing CIPN in patients with primary breast cancer receiving taxane-based chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: The POLAR randomized clinical trial was conducted at the National Center for Tumor Diseases Heidelberg between November 2019 and January 2022. Female patients with breast cancer who received weekly nab-paclitaxel-based or paclitaxel-based neoadjuvant or adjuvant chemotherapy were enrolled. Patients with prior chemotherapy, preexisting neuropathy, or neuropathy-related comorbidities were excluded. INTERVENTIONS: Patients were randomized 1:1 to cooling or compression of the dominant hand. No intervention was performed on the other hand. Cooling was performed with a frozen glove and compression was applied by 2 surgical gloves (1 size smaller than the tight-fitting size) 30 minutes before, after, and during taxane administration. MAIN OUTCOMES AND MEASURES: The primary end point was the efficacy to prevent grade 2 or higher sensory CIPN evaluated by Common Terminology Criteria for Adverse Events, version 5.0. Further CIPN assessment included the clinical version of the Total Neuropathy Score and QLQ CIPN20. CIPN rates were compared between intervention groups. Nail toxic effects, quality of life, CIPN-associated dose reductions, treatment discontinuations, and risk factors were evaluated. Follow-up examinations were performed 1 week, 1 month, and 6 to 8 months after the last taxane dose. RESULTS: A total of 122 female patients with primary breast cancer (mean [SD] age, 50 [12] years) were randomized to either cooling or compression of the dominant hand. Twenty-one individuals withdrew from the study, so 101 patients were included in the final analysis (n = 52 and n = 49 for cooling and compression, respectively). Both interventions significantly reduced the incidence of grade 2 or higher CIPN (cooling: 15 participants experiencing high-grade CIPN in the cooling arm [29%] vs 26 in the control arm [50%]; P = .002; effect size, 21.15% [95% CI, 5.98%-35.55%]; compression: 12 participants experiencing CIPN in the intervention arm [24%] vs 19 in the control arm [38%]; P = .008; effect size, 14.29% [95% CI, 2.02%-27.24%]). CIPN was the main reason for treatment discontinuations in 16 of 24 participants (67%). The predominant risk factors were the cumulative taxane dosage and the neurotoxic agent. Participants experiencing grade 2 or higher CIPN showed a reduced global health status during and 6 to 8 months after taxane therapy. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, cooling and compression were highly effective and significantly reduced the risk of high-grade CIPN. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06541769.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Michel LL, Schwarz D, Romar P, et al. Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy: The POLAR Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 40048176. doi:10.1001/jamaoncol.2025.0001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。